Advertisements


ADMA Biologics: FDA establishes target action date of Dec. 18 for Bivigam PAS

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallOct 11th, 2018

ADMA Biologics receives PDUFA date for BIVIGAM regulatory submission

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJul 26th, 2018

ADMA Biologics receives PDUFA date of April 2, 2019 for RI-002

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallOct 17th, 2018

ADMA Biologics: Buy Or Sell Before Bivigam PDUFA?

ADMA Biologics: Buy Or Sell Before Bivigam PDUFA?.....»»

Category: topSource: seekingalphaAug 31st, 2018

ADMA Biologics price target raised to $12 from $10 at Maxim

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJul 26th, 2018

ADMA Biologics price target lowered to $7.50 from $10 at Ladenburg

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 13th, 2018

FDA Confirms September Action Date for Teva"s Migraine Drug

Teva (TEVA) confirms that FDA has extended the goal date of the Biologics License Application (BLA) for fremanezumab to September from mid-June. Teva Pharmaceutical Industries Ltd. TEVA confirmed that FDA has extended t.....»»

Category: smallbizSource: nytMay 24th, 2018

Invesco High Income 2023 Target Term Fund (IHIT) Ex-Dividend Date Scheduled for October 15, 2018

Invesco High Income 20.....»»

Category: futuresSource: nasdaqOct 12th, 2018

ADMA Biologics: FDA requires additional 2 months to complete review of PAS

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallOct 11th, 2018

ADMA Biologics: FDA considers response to information request "major amendment"

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallOct 11th, 2018

Piper remains buyer of Regeneron ahead of October 20 FDA action date

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallOct 11th, 2018

FDA Sets Action Date for Recro"s Pain Management Candidate

The FDA has set an action date of Mar 24, 2019 for Recro's lead product candidate, intravenous (IV) meloxicam, for the management of moderate to severe pain. Recro Pharma, Inc. REPH announced that the FDA has set an action dat.....»»

Category: dealsSource: nytOct 9th, 2018

ADMA Biologics receives FDA approval for third plasma collection center

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallOct 3rd, 2018

ADMA Biologics resubmits biologics license application for BI-002

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallOct 1st, 2018

ADMA Biologics responds to 2016 CRL, resubmits BLA for RI-002

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallOct 1st, 2018

Bank Of America Raises Nvidia Price Target To A Street High, Sees Upside In Multiple Segments

Shares of NVIDIA Corporation (NASDAQ: NVDA), which have rallied about 38 percent year-to-date, have additional runway for upside ahead, according to Bank of America Merrill Lynch. Latest Ratings f.....»»

Category: blogSource: benzingaSep 25th, 2018

The Case for Breaking Up Amazon

With big tech companies facing increasing public scrutiny and Amazon the preferred target of President Donald Trump, the company could get ahead of any government action......»»

Category: topSource: barronsSep 19th, 2018

UBS: Market Now Understands Durability Of Fortinet"s Business

Fortinet Inc (NASDAQ: FTNT) shares have doubled year-to-date, sendingĀ UBS to the sidelines. The Analyst Analyst Fatima Boolani downgraded shares of Fortinet from Buy to Neutral and lifted the price target from $80 to $90. Latest Rati.....»»

Category: blogSource: benzingaSep 18th, 2018

Employers are using Facebook to target job ads for police officers, truck drivers and sports store clerks exclusively to men

A legal action accuses Facebook and 10 employers of discrimination for targeting ads exclusively to men......»»

Category: topSource: washpostSep 18th, 2018

Employers are using Facebook to target job ads for police officers, truck drivers and sports store clerks exclusively to men

A legal action accuses Facebook and 10 employers of discrimination for targeting ads exclusively to men......»»

Category: topSource: washpostSep 18th, 2018

Fidelity Investments winds down $3.5 billion index fund

Fidelity Investments is winding down a fund that had more than $3 billion in assets last year, with the Boston-based money manager citing an overlap in holdings of other funds used in its target-date products to explain the rare move......»»

Category: topSource: reutersSep 13th, 2018